PDL BioPharma, Inc.
(NASDAQ : PDLI)

( )
PDLI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -16.36%57.710.0%$1537.44m
GILDGilead Sciences, Inc. -0.22%73.181.0%$1287.43m
AMGNAmgen, Inc. -1.78%222.401.3%$637.47m
REGNRegeneron Pharmaceuticals, Inc. -4.33%545.212.5%$616.99m
NVAXNovavax, Inc. 4.47%48.17102.0%$608.66m
VRTXVertex Pharmaceuticals, Inc. -6.48%266.501.9%$516.32m
BIIBBiogen, Inc. -2.84%295.871.6%$413.02m
ILMNIllumina, Inc. -0.08%354.413.5%$354.75m
SRNESorrento Therapeutics, Inc. 3.95%5.271.8%$307.06m
SGENSeattle Genetics, Inc. -2.59%151.736.1%$243.04m
ALXNAlexion Pharmaceuticals, Inc. 1.28%102.802.0%$224.06m
AAgilent Technologies, Inc. 1.37%86.141.6%$196.15m
CODXCo-Diagnostics, Inc. -2.80%18.030.0%$185.93m
MGNXMacroGenics, Inc. -6.82%23.646.2%$178.27m
BMRNBioMarin Pharmaceutical, Inc. 6.39%103.744.3%$172.63m

Company Profile

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.